Real World Data on CAR T-Cell Recipients: Are We There Yet?
Drs. Marcelo Pasquini and Miguel-Angel Perales discuss the history and significance of the Center for International Blood and Marrow Transplant Research (CIBMTR), a decades
A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients
Dr. DeZern discusses two studies that show improved outcomes for older patients with AML using a venetoclax and hypomethylating agents combination.
Dr. Moss reviews studies that show the usefulness of chimeric antigen receptor T-cell therapy in the management of relapsed large B-cell lymphoma.
Dr. Moss looks at a study that focuses on the activity of prophylactic emicizumab in patients with hemophilia who do not have inhibitors.
Dr. Moss reviews a study that looks at selective forces that drive the migration of the hematopoietic niche into bone.
Dr. Moss reviews a study that demonstrates the success of using gene therapy for the genetic correction of thalassemia.
Dr. Moss discusses the CLARITY study, which looks at the combination of therapies venetoclax and ibrutinib to treat relapsed/refractory chronic lymphocytic leukemia.
Dr. Moss reviews the pathogenesis and potential eradication of favism.
Dr. Moss covers several trials that have solidified the use of venetoclax as the new backbone within a range of combination therapies that should achieve extremely deep therapeutic responses in CLL.
Dr. Moss evaluates a case that requires CAR-T cell therapy and discusses practical issues hematologists should be aware of during introduction of this treatment.
Dr. Moss covers a radical revision of the classification of dendritic cells and monocytes.
Dr. Moss reviews the first trial to show that an immunotherapeutic agent improves survival over chemotherapy in relapsed or refractory ALL patients.
January-February 2019Volume 16, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology